Conferences - Results from #580

Viewing 581-600 of 11775 articles

AUA 2024: Journal of Urology Lecture: Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color

AUA 2024: Development and External Validation of an Artificial Intelligence-Based Tool for PROGression Risk Assessment in Non-Muscle Invasive Bladder Cancer (PROGRxN-BCa)

AUA 2024: Comprehensive Evaluation of Response to Immune Checkpoint Blockade in Primary Tumor: Radiographic and Radiomic Features Predict Pathologic Response in Primary Tumor

AUA 2024: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC): Phase 3 Preliminary Results

AUA 2024: Computer Vision Analysis of Upper Tract Urothelial Carcinoma to Predict High vs Low Grade Pathology

AUA 2024: Development and Validation of Generalizable Interpretable AI Biomarkers to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer

AUA 2024: Survival is Dramatically Improved for mRCC Patients with Sarcomatoid Features who are Treated with Cytoreductive Nephrectomy and Immune Checkpoint Inhibitors Regardless of Treatment Sequence

AUA 2024: Tumor Size Reduction (≥10% ) Resulting from Pre-Surgical Systemic Therapy Predicts Improved Survival Following Cytoreductive Nephrectomy

AUA 2024: Predicting Response to Intravesical BCG in High Risk Non-Muscle Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12 Center Cohort

AUA 2024: State-of-the-Art Lecture: Advances in Molecular Imaging for Renal Tumors

AUA 2024: Phase I Study of Intravesical Fc-Optimized Anti-CD40 Agonist Antibody 2141-V11 for Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

AUA 2024: Midlife Baseline PSA as a Predictor of Lethal Prostate Cancer: Racial Differences between Black and White Men

AUA 2024: Paradigm-Shifting Clinical Trials in Urology: SWOG S1011 - Subgroup Analysis of the Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for MIBC

AUA 2024: Exploring the Dual Impact to Treatment Outcomes in Patients with Short Time to Nadir PSA Under Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer

AUA 2024: Development of a Novel Risk Stratification for Prostate Cancer Patients Candidate to Radical Prostatectomy Staged with Preoperative PSMA-PET: The Key Role of Molecular Imaging

AUA 2024: Predicting Positive 68Ga-PSMA PET/CT Scans in Biochemical Recurrence Following Prostatectomy.

AUA 2024: Comparison of 68-Ga-PSMA PET/CT and Multiparametric MRI in Detecting Lymph Node Metastases in Patients with Intermediate or High-Risk Prostate Cancer

AUA 2024: Combination Regimen of Intravesical Docetaxel, Gemcitabine, and Cisplatin in Patients with BCG-unresponsive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

AUA 2024: Integrating MR and Ultrasound Images for AI-based Prostate Cancer Detection in Transrectal Ultrasound Images: A Comparative Assessment with Clinicians

AUA 2024: Characteristics of PI-RADS 5 Lesions with a Negative or Gleason Grade Group 1 Biopsy

25
26
27
28
29
30
31
32
33
34